Literature DB >> 7373617

Analysis of treatment terminations with gold and antimalarial compounds in rheumatoid arthritis.

J A Richter, L A Runge, R S Pinals, R P Oates.   

Abstract

Life table analysis was used to determine the incidence of treatment termination in rheumatoid arthritis patients after initial therapeutic courses of gold (93) and antimalarial compounds (101). Patients treated with antimalarial compounds tended to terminate treatment sooner than those receiving gold. The most common reasons for discontinuing antimalarial therapy were lack of initial benefit and loss of response to the drug. Clinical and laboratory characteristics of patients at onset of therapy did not influence failure rates to a great extent.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373617

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Long-term effectiveness of antimalarial drugs in rheumatic diseases.

Authors:  J A Aviña-Zubieta; G Galindo-Rodriguez; S Newman; M E Suarez-Almazor; A S Russell
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

2.  Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective.

Authors: 
Journal:  Ann Rheum Dis       Date:  1982       Impact factor: 19.103

Review 3.  Comparative effectiveness research with administrative health data in rheumatoid arthritis.

Authors:  Marie Hudson; Koray Tascilar; Samy Suissa
Journal:  Nat Rev Rheumatol       Date:  2016-04-15       Impact factor: 20.543

Review 4.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods.

Authors:  R D Situnayake; K A Grindulis; B McConkey
Journal:  Ann Rheum Dis       Date:  1987-03       Impact factor: 19.103

6.  Bioavailability of hydroxychloroquine tablets in healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

7.  Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  E F Morand; P I McCloud; G O Littlejohn
Journal:  Ann Rheum Dis       Date:  1992-12       Impact factor: 19.103

8.  Injectable gold-induced hepatitis and neutropenia in rheumatoid arthritis.

Authors:  W S Uhm; D H Yoo; J H Lee; T H Kim; J B Jun; I H Lee; S C Bae; S Y Kim
Journal:  Korean J Intern Med       Date:  2000-07       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.